Xeris Pharmaceuticals (XERS) Receives a Buy from Mizuho Securities


Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $14.00. The company’s shares closed last Thursday at $4.66.

According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.7% and a 37.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Selecta Biosciences, and Akebia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $12.50 average price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Read More on XERS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts